Publication

Article

Pharmaceutical Executive

Pharmaceutical Executive-10-01-2020
Volume40
Issue 10

Pharmaceutical Executive, October 2020 Issue (PDF)

Click the title above for a link to open the Pharmaceutical Executive October 2020 issue in an interactive PDF format.

Click the cover for PDF

Download Issue PDF
Articles in this issue
The SPAC Makes a Comeback!
The SPAC Makes a Comeback!
Leadership and Industry Image
Leadership and Industry Image
Assets in Anxious Times: Patient Hubs Demonstrate Value During COVID-19
Assets in Anxious Times: Patient Hubs Demonstrate Value During COVID-19
The Interplay Between COVID-19 Pandemic and NCD Epidemic
The Interplay Between COVID-19 Pandemic and NCD Epidemic
FDA Struggles to Retain Credibility
FDA Struggles to Retain Credibility
Critical Connection: Patient Services and Product Launch
Critical Connection: Patient Services and Product Launch

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Derrick Gastineau
Related Content
Stock.adobe.com
August 29th 2025

Replicate Bioscience Announces Partnership with Novo Nordisk Aimed at Unlocking Self-Replicating RNA Therapies

Nicholas Jacobus
The Rx for High-Performance Leadership: Cutting Through the Chaos
August 29th 2025

The Rx for High-Performance Leadership: Cutting Through the Chaos

Michael Christel
Robert F. Kennedy Jr.
August 29th 2025

Susan Monarez Rejects Removal as CDC Director Even After White House Steps In

Mike Hollan
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 29th 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
Stock.adobe.com
August 29th 2025

FDA Accepts New Drug Application for Gadoquatrane

Nicholas Jacobus
Credit: Tada Images | stock.adobe.com, The FDA has authorized the use of updated COVID-19 vaccines for the upcoming fall season, with eligibility limited to adults aged 65 years and older as well as individuals who have at least one underlying medical condition that places them with a high risk for severe COVID-19
August 29th 2025

FDA Authorizes New COVID Vaccines with Restrictions on Eligibility

Davy James